Reuters logo
BRIEF-Hybrigenics announces results from Phase II study on inecalcitol
February 9, 2017 / 5:38 PM / 7 months ago

BRIEF-Hybrigenics announces results from Phase II study on inecalcitol

Feb 9 (Reuters) - Hybrigenics SA:

* Announces encouraging preliminary results from the Phase II clinical study of inecalcitol in Chronic Myelogenous Leukemia

* At this intermediate stage of study, 43 percent of the patients (6 out of 14) have shown further decrease in bcr-abl from mmr at three months

* After one year of treatment, 33 percent (3 out of 9) have demonstrated reduction in BCR-ABL beyond DMR, i.e. undetectable biomarker traces

* The sample size of this pilot study has been reduced to 42 patients, with a target completion in H2 2018 Source text: bit.ly/2k8iSuO Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below